The FDA has given the all-clear to AI software that measures nodules in the lungs, a tedious but important task for radiologists monitoring changes in these growths over time.
An AI system for diagnosing prostate cancer on biopsy slides has achieved 98%-plus performance in sensitivity, positive predictive value, specificity and negative predictive value.
Noting that multiple sclerosis now affects more people between 50 and 60 than any other age group, researchers have shown how machine-learning gait analysis can help personalize therapy regimens.
Academic researchers in the U.K. have completed a systematic review of 62 representative studies on the use of AI for COVID-19 diagnostics and prognostics on X-rays and CT scans. Their findings may strike some as a setback.
The FDA has granted 510(k) clearance to clinical decision support software that uses AI to detect small but potentially cancerous lesions in the lungs.
The FDA has blessed an AI-packing armband that checks for biometric patterns pointing to possible SARS-CoV-2 infection in individuals with no symptoms.
Researchers have demonstrated that deep learning models can help neurologists interpret epileptic episodes during and between seizures from relatively few scalp electroencephalography (EEG) readings.
The European Union has granted CE mark approval to a U.S.-based maker of AI software that aids radiologists in distinguishing between benign and malignant lesions on breast ultrasound images.
The FDA has greenlit an AI algorithm that automatically measures dilation in the heart’s right ventricle on CT images.
An MIT spinoff based in Boston and Milan in Italy has earned CE certification for software that flags respiratory infection in wearers of the company’s smartwatch devices.
A manufacturer of compact MRI machines that leverage AI to upgrade image quality has received FDA’s blessing to market its technology in the U.S.
The advance represents the first cancer-care pathway offering an automatically combined analysis of morphological, molecular and histological data.
Two different companies announced that they are recalling all lots of the medication.
CardioSmart, an online resource for both patients and clinicians, has a new editor.
The funding includes $8.5 billion in American Rescue Plan resources for providers who treat Medicaid, Children's Health Insurance Program and Medicare patients.